Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Autor: Bellera CA; Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux. Electronic address: c.bellera@bordeaux.unicancer.fr., Penel N; Department of Medical Oncology, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France., Ouali M; Department of Biostatistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Biostatistics Unit, Institut Claudius Regaud, Comprehensive Cancer Centre, Toulouse., Bonvalot S; Department of Surgery, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France., Casali PG; Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Nielsen OS; Faculty of Health Sciences, Aarhus University, Aarhus, Denmark., Delannes M; Department of Radiotherapy, Institut Claudius Régaud, Comprehensive Cancer Center, Toulouse., Litière S; Department of Biostatistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Bonnetain F; Methodological and Quality of Life Unit in Oncology (EA3181), CHU Besançon, Besançon., Dabakuyo TS; Biostatistics and Quality of Life Unit (EA4184), Centre Georges-François Leclerc, Comprehensive Cancer Centre, Dijon, France., Benjamin RS; Division of Cancer Medicine and Sarcoma Center, The University of Texas M.D. Anderson Cancer Center, Houston, USA., Blay JY; Department of Medical Oncology, Centre Léon Bérard, Comprehensive Cancer Centre, Lyon; Claude Bernard Lyon I University, Lyon; Medical Oncology Unit, Edouard Herriot Hospital, Lyon., Bui BN; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux., Collin F; Department of Biology and Pathology, Centre Georges-François Leclerc, Comprehensive Cancer Centre, Dijon, France., Delaney TF; Department of Radiation Oncology and Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, USA., Duffaud F; Department of Medical Oncology, La Timone Hospital University, Marseille, France., Filleron T; Biostatistics Unit, Institut Claudius Regaud, Comprehensive Cancer Centre, Toulouse., Fiore M; Department of Surgery and Sarcoma Unit, Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gelderblom H; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., George S; Department of Medical Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Grimer R; Royal Orthopaedic Hospital NHS Trust, Birmingham, UK., Grosclaude P; Cancer Registry of Tarn, Institut Claudius Regaud, Comprehensive Cancer Centre, Toulouse, France., Gronchi A; Department of Surgery and Sarcoma Unit, Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Haas R; Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Hohenberger P; Division of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, Mannheim., Issels R; Sarcoma Center, Ludwig-Maximilian University Munich, Munich; Department of Internal Medicine, Klinikum Grosshadern Medical Center, University of Munich, Munich, Germany., Italiano A; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux., Jooste V; Burgundy Digestive Cancer Registry, INSERM U866, University of Burgundy, Dijon, France., Krarup-Hansen A; Department of Oncology, Herlev Hospital-University Copenhagen, Herlev, Denmark., Le Péchoux C; Department of Radiotherapy, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France., Mussi C; Department of Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy., Oberlin O; Department of Surgery and Department of Pediatric and Adolescent Oncology, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif., Patel S; Division of Cancer Medicine and Sarcoma Center, The University of Texas M.D. Anderson Cancer Center, Houston, USA., Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Comprehensive Cancer Centre, Paris, France., Raut C; Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Ray-Coquard I; Department of Medical Oncology, Centre Léon Bérard, Comprehensive Cancer Centre, Lyon., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland., Schuetze S; Department of Medical Oncology, University of Michigan, Ann Arbor, USA., Sleijfer S; Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands., Stoeckle E; Department of Surgical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France., Van Glabbeke M; Department of Biostatistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Woll P; Department of Oncology, Sheffield Cancer Research Centre, Weston Park Hospital, Sheffield, UK., Gourgou-Bourgade S; Montpellier Cancer Institute, Comprehensive Cancer Centre, Montpellier, France., Mathoulin-Pélissier S; Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2015 May; Vol. 26 (5), pp. 865-872. Date of Electronic Publication: 2014 Jul 28.

Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.

Autor: Dabakuyo TS; Breast and Gynecologic Cancer Registry of Côte d'Or, Centre Georges François Leclerc, Dijon, EA 4184, France. sdabakuyo@cgfl.fr, Arnaud A, Maingon P, Causeret S, Coudert B, Fumoleau P, Arnould L, Poillot ML, Arveux P, Crehange G, Bonnetain F

Publikováno v: European journal of cancer care [Eur J Cancer Care (Engl)] 2013 Sep; Vol. 22 (5), pp. 638-47. Date of Electronic Publication: 2013 May 05.

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.

Autor: Bellera CA; Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France., Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2013 Mar; Vol. 49 (4), pp. 769-81. Date of Electronic Publication: 2012 Nov 02.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

Autor: Zaanan A; Service d'Hépato-Gastroentérologie et Oncologie digestive, Hôpital Européen Georges Pompidou, AP-HP, Paris, France., Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, Bonnetain F, Boige V, Taïeb J

Publikováno v: Journal of hepatology [J Hepatol] 2013 Jan; Vol. 58 (1), pp. 81-8. Date of Electronic Publication: 2012 Sep 16.

Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment.

Autor: Dialla PO; Breast and Gynaecologic Cancer Registry of Cote d'Or, Centre Georges François Leclerc, 1 rue Professeur Marion BP 77980, Dijon Cedex 21079, France., Dabakuyo TS, Marilier S, Gentil J, Roignot P, Darut-Jouve A, Poillot ML, Quipourt V, Arveux P

Publikováno v: BMC cancer [BMC Cancer] 2012 Oct 15; Vol. 12, pp. 472. Date of Electronic Publication: 2012 Oct 15.